MK-677 vs Somatropin — mechanism, half-life, dosing, and research status compared. Which is right for your protocol?
MK-677 (ibutamoren) is an orally active, non-peptide ghrelin receptor agonist (GHS-R1a) that stimulates GH release from the pituitary without requiring injection. It was developed by Merck and advanced through Phase II trials for growth hormone deficiency, muscle wasting, and fra...
Calculate MK-677 dose →Somatropin is recombinant human growth hormone (rhGH) - a 191 amino acid protein identical to endogenous pituitary GH, produced via recombinant DNA technology. It is FDA-approved for multiple indications including pediatric and adult growth hormone deficiency, Turner syndrome, HI...
Calculate Somatropin dose →| Parameter | MK-677 | Somatropin |
|---|---|---|
| Category | Growth Hormone & IGF | Growth Hormone & IGF |
| Research | Phase II (Discontinued) | FDA Approved |
| Half-Life | ~24 hours | ~3–4 hours (SubQ); ~20 min (IV) |
| Typical Dose | 10–25 mg | 0.1–0.3 mg/day (GHD); up to 2 mg/day (clinical indications) |
| Frequency | Once daily | Daily or 6 days/week |
| Route | Oral | Subcutaneous / Intramuscular |
| FDA Status | Not Approved | Approved |
Use ASCEND's free reconstitution calculator to get exact syringe draw amounts for your vial.
For research use only. Not medical advice. ASCEND does not conduct or endorse any specific research protocol. Always consult relevant scientific literature and regulatory guidelines.